Therapeutic complement inhibition by eculizumab has revolutionized the treatment of paroxysmal nocturnal hemoglobinuria (PNH) with a major impact on its natural history. Nevertheless, emerging unmet clinical needs may benefit from the development of novel complement inhibitors. Novel 
| I N TR ODU C TI ON
2 Two subsequent phase III registration trials demonstrated a dramatic reduction of intravascular hemolysis, which led to hemoglobin stabilization and transfusion independency in about half of patients. 3, 4 In addition to the control of all hemolysis-related symptoms and to improved quality of life, sustained inhibition of terminal complement resulted in a marked reduction of the thromboembolic events typical of PNH. 5 The actual mechanism of action of this effect has not been fully elucidated, since it is not clear whether it is simply due to an indirect effect which follows the inhibition of intravascular hemolysis, or it may also include a direct effect of complement inhibition on the pathogenic mechanisms of thrombosis in PNH (which appears to be multi-factorial). This remarkable clinical effect was obtained without major safety concerns, including the feared risk of infectious complications (all patients on eculizumab receive broad vaccinations against Neisseria Meningitidis).
3-5
The long-term use of eculizumab in PNH is more than a supportive treatment; two independent studies have clearly demonstrated that the survival of PNH patients on eculizumab exceeds 90% at 5 years, 6, 7 which is by far higher than what known from previous natural history data. 8, 9 Thus, even if the only curative option for PNH remains hematopoietic stem cell transplantation, 10 eculizumab is the current gold standard for PNH patients presenting with hemolytic and/or thromboembolic disease. However, eculizumab (as any other future anticomplement treatment) has no effect on the bone marrow disorder underlying PNH, which mostly appears as bone marrow failure but may also lead to evolution to hematological malignancies. 7 Nevertheless, some unmet clinical needs emerged in the era of eculizumab: (i) insufficient clinical benefit, seen as residual anemia; (ii) heaviness of life-long bi-monthly intravenous (IV) infusions; (iii) limited access to treatment due to elevated cost. The first point represents the main driver to develop novel strategies of therapeutic complement inhibition. True resistance to eculizumab has been documented only in a few patients, mostly of Japanese ethnicity, carrying an inherited polymorphism of C5. 11 However, even in patients with documented complement blockade, the hematological benefit is quite heterogeneous: indeed, residual anemia affects about most PNH patients on eculizumab, and about one third still requires red blood cell transfusions. 3, 4, [12] [13] [14] The most obvious cause of such residual anemia is inadequate compensatory erythropoiesis due to the wellestablished overlap between aplastic anemia (AA) and PNH 15 ; these patients should receive the appropriate treatment according to the AA algorithm. [16] [17] [18] However, the vast majority of PNH patients on eculizumab remain anemic irrespective of increased reticulocyte count, eventually documenting residual hemolysis even during anti-C5
treatment. In 15%-20% of patients this is due to residual intravascular hemolysis which regularly occurs 1-2 days before the next dosing of eculizumab (the so-called "pharmacokinetic [PK] breakthrough") 14 ;
these patients may benefit from increased doses (1200 mg) or reduced dosing intervals (10 days) of eculizumab. 19 This modified treatment schedule has a limited effect to control the "pharmacodynamic [PD] breakthrough" (which rather is seen as low-grade continuous intravascular hemolysis) and possible hemolytic paroxysms in concomitance with massive complement activation. 20, 21 However, the most common cause of residual anemia in PNH patients on eculizumab was identified in C3-mediated extravascular hemolysis. 12 This phenomenon mechanistically pertains to all PNH patients on eculizumab as a result of upper (upstream C5) complement activation, which remains uncontrolled irrespective of C5 blockade. 12 As a result, pro- ; nevertheless, C3-mediated extravascular hemolysis impairs hematological response to eculizumab in 25%-50% of patients. 7, 12, 14, 25 The reasons accounting for such heterogeneous clinical importance may include possible genetic variants of complement-related genes, as reported for the hypomorphic variant of complement receptor 1 (CR1) gene. 26 While the use of steroids is discouraged, 24 splenectomy has been anecdotically reported effective to treat C3-mediated extravascular hemolysis 27, 28 ; however, at the moment there is no reliable treatment option for this common event emerging during eculizumab treatment. 29 
| N OVE L STRA TE GI E S OF COM P L EM E NT I NH I BI TI ON
A plethora of agents is currently in the pipeline of several pharmaceutical companies 30 ; they can be divided according to their target in the complement cascade 31 ( Figure 1 ; Table 1 ). Inhibitors of the effector pathway target C5, and include at least 6 novel mAb-derived compounds, 32-36 a small-interfering RNA (siRNA) 37 and 2 small molecules. [38] [39] [40] [41] [42] [43] A second group of inhibitors intercept the complement cascade upstream C5; they include broad inhibitors of C3 and agents which specifically target complement activating pathways-classical (CCP), alternative (CAP), and mannose/lectine (CMP) ones ( Figure 1 ; Table 1 ). 31 For PNH, candidate inhibitors target the CAP, inhibiting C3
convertase C3bBb, [50] [51] [52] [53] [54] [55] or one of CAP key early components, ie, factor D (FD), [56] [57] [58] factor B (FB), 59, 60 and properdin. These upstream inhibitors include mAb, small compounds, as well as engineered proteins based on endogenous regulators of complement activation. 50 Here, we summarize publically available information, describing the ongoing trials with their design (Table 2 ) and available data.
| ABP959 (Amgen)
The anti-C5 mAb ABP959 was initially tested in Australia in a phase I randomized trial investigating PK and PD of this compound as compared to eculizumab (ACTRN12616000509460). 61 Data are not publi-
cally available yet; nevertheless, a large phase III randomized trial is currently ongoing in Europe (EudraCT Number 2017-001418-27).
32
Since this compound has been announced as a biosimilar of eculizumab (even if the true meaning of this term may be questioned until details about drug manufacturing will be available), safety and efficacy profile should parallel those of eculizumab, and no further scientific discussion about ABP959 is provided.
| ALXN1210 (Alexion)
ALXN1210 is an anti-C5 mAb sharing with eculizumab the same target epitope. A phase I study of ALXN1210 in healthy volunteers demonstrated immediate, complete, and sustained C5 inhibition, with a terminal half-life about 4-fold longer than eculizumab. 32 Then, ALXN1210
was investigated in two phase I/II trials (NCT02598583 and NCT02605993) which enrolled 13 and 26 untreated PNH patients, aiming to evaluate safety, tolerability, and efficacy of different IV dosing regimens. 62, 63 No death, serious adverse event, drug discontinuation, or adverse event (AE) leading to withdrawals were recorded.
64
ALXN1210 demonstrated rapid, complete, and sustained C5 inhibition, eventually leading to prompt and sustained LDH reduction and frequent hemoglobin stabilization in all treatment cohorts. 64, 65 Patients receiving 600 and 900 mg as loading dose, followed by maintenance with 1800 mg every 4 weeks, showed the best outcome in terms of sustained control of intravascular hemolysis (LDH normalization in 6/7
and no breakthrough episode). 65 Notably, two patients on ALXN1210
experienced sepsis by N. Meningiditis
65
; both patients completely recovered after ceftriaxone treatment, and continued ALXN1210.
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Two large phase III trials are now comparing ALXN1210 used at 3300 mg every 8 weeks (maintenance dose, after a loading dose of 2700 mg) with the standard treatment eculizumab, both as initial treatment for PNH (NCT02946463), 66 and switch therapy for patients already on eculizumab (NCT03056040) with adequate control of hemolysis (LDH <1.5x ULN). 67 Notably, in both studies changes in LDH levels appear as primary endpoint, likely because of a deeper C5 inhibition initially seen with ALXN1210, 65 which may result in a better control of chronic intravascular hemolysis (eg, less PK and/or PD breakthrough). The clinical meaning of this more profound complement inhibition (with possible increased infectious risk) 65 will have to be investigated (low-level residual C5 activity seen with eculizumab 21 might be somehow protective from infectious agents). Nevertheless, the most obvious benefit from this long-lasting C5 inhibitor will pertain to patients' convenience in terms of treatment ease, as a result of the two-month dosing interval (even if still IV). The more profound C5 inhibition might also anticipate some benefit in patients experiencing frequent breakthrough, but at the moment this population was excluded from ongoing trials. 31 The three activating pathways are individually depicted, together with the alternative pathway amplification loop; they eventually lead to the C5 cleavage by C5 convertase (C3bBbC3b or C4b2aC3b), which arms the effector pathway of the complement cascade. 31 Candidate inhibitors are grouped according to their specific target; their modulatory effects are indicated by red lines intercepting specific steps of the complement cascade. 30 Therapeutic interception of the complement cascade may occur: i. at the level of its common terminal complement effector pathway (eg, C5); ii. at the level of its common key activation and amplification component (ie, C3); iii. at the level of pathway-specific initiating events. For the purpose of PNH, for this latter target only the CAP is considered, since the role of CCP and CMP in the pathophysiology of PNH is considered somehow limited (even if experimental evidences are lacking). (B) PNH pathogenic events eventually targeted by novel anticomplement agents. CAP inhibitors and C3 inhibitors both disable C3 activation, which results from C3 tick-over and in presence of therapeutic C5 inhibition leads to C3 opsonization of PNH erythrocytes. As a consequence, both CAP-inhibitors and C3 inhibitors anticipate therapeutic efficacy in preventing C3-mediated extravascular hemolysis. Mechanistically, this upstream inhibition should also prevent down-stream events of the terminal complement effector pathway; indeed, intravascular hemolysis should be prevented as well. Novel C5 inhibitors disable the terminal complement effector pathway, which usually result in intravascular hemolysis. In addition to represent an alternative to standard treatment eculizumab, these novel agents may result in a deeper C5 inhibition, eventually leading to the prevention of both pharmacokinetic and pharmacodynamics breakthrough possibly occurring during eculizumab treatment [Color figure can be viewed at wileyonlinelibrary.com] 
| LFG316 (Novartis)
A proof-of-concept phase I study is currently investigating LFG316 in untreated PNH patients in Japan (NCT02534909); the primary endpoint of the study is biological efficacy, as measured by LDH change.
35
LFG316 may represent an option for patients carrying C5 polymorphisms associated with intrinsic resistance to eculizumab. 
| ALNCC5 (Alnylam)
ALNCC5 is a small interfering RNA (si-RNA) duplex specific for C5, which is able to completely silence C5 production from the liver in animal models. 37 ALNCC5 was proven safe and effective in healthy individuals (n 5 32), resulting in >99% reduction of C5 plasma level and >95% inhibition of serum complement activity. 69, 70 This phase I/II first-in-human trial (NCT02352493) also included an arm enrolling PNH patients 69 ; data were presented at ASH 2016. 71 Six patients received ALNCC5 at weekly doses (200 or 400 mg, SC), 3 in monotherapy (untreated patients) and 3 on top of fortnightly eculizumab (one with persistent breakthrough). No severe AE was observed, nor AE requiring treatment discontinuation; one patient developed increased transaminases. 71 In untreated patients, ALNCC5 resulted in C5 knockdown >98%
70
; however, given the mechanism of action of this compound, the knockdown is established slowly and requires about two months to achieve therapeutic inhibition (which is definitely not acceptable for PNH patients requiring immediate intervention, eg, those with thromboembolic complications). 70 Nevertheless, LDH reduction (37% and 50%) was observed only in 2 of 3 patients with very high baseline LDH (>5x ULN); residual low-level hemolysis with LDH >1.5x ULN remained in all 3 patients. 71 This was consistent with data using C5-depleted sera in an in vitro model of PNH, 48, 52 where the addition of recombinant C5 in amount as low as 0.9 mg/mL (equal to about 1% of normal C5 plasma level) restored >90% of the complement-mediated hemolytic activity (Risitano et al, unpublished observation). Nevertheless, these PNH patients treated in monotherapy with ALNCC5 then benefited from the addition of eculizumab, which resulted in full control of residual intravascular hemolysis at doses as low as about 25% of standard ones (600 mg monthly). 71 The potential efficacy of a combined treatment with ALNCC5 and eculizumab was also investigated in the 3 patients already on eculizumab;
here, combined treatment resulted in LDH normalization, even in the patient experiencing breakthrough (who was able to reduce eculizumab at the standard schedule of 900 mg every other week). 71 Based on these data, the best setting for further development of ALNCC5 in PNH is in combination with eculizumab, as currently under investigation in an ongoing trial aiming to improve response in poor responders (EudraCT Number 2016-002943-40) 72 ; this combination therapy may also represent an option to achieve deeper control of residual intravascular hemolysis, and/or reduce the dosing of eculizumab.
| Coversin (Akari)
Coversin is a 16 kDa protein derived from the tick Ornithodoros moubata 38 able to prevent C5 cleavage by its convertases 38 ; its in vitro 74 Out of the first 5 patients enrolled, four remained on coversin (one was withdrawn because of possible co-morbidity). 75 Coversin was well tolerated, with mild injection site reactions as only AE; no high-titer neutralizing antibodies were demonstrated. LDH reduction was observed in all patients, even if only two of them reached the primary endpoint of the study (LDH <1.8x ULN); irrespective of this residual hemolysis, no red cell transfusion was needed during the three-month period of the study. 75 According to authors' conclusions, this residual intravascular hemolysis is not related to sub-therapeutic plasma levels of coversin, since terminal complement activity, as assessed by CH50, remained fully inhibited along the study. 75 These data demonstrate that coversin has biological efficacy in PNH, with acceptable safety profile, and the benefit of possible selfadministration; nevertheless, likely the treatment regimen needs to be optimized (residual intravascular hemolysis is quite frequent), and the concerns about possible neutralizing antibodies requires further investigations which are already ongoing in an extension trial (EudraCT Number 2016-004129-18). 76 
| RA101495 (Rapharma)
Rapharma is developing small synthetic, macrocyclic peptides (named cyclomimetic) with excellent bioavailability (even orally) 41, 42, 77 and in vitro efficacy in PNH. 42, 43 Their lead compound RA101495 43 was safe and well tolerated as SC injections in healthy volunteers, with only mild local irritation 78 ; a daily dosing allowed full (>95%) and sustained suppression of complement activity. 79 Two parallel phase II study were started: study NCT03078582 investigated a loading dose of 0.3 mg/kg followed by 0.1 mg/kg daily in both untreated and eculizumab-treated PNH patients with LDH >2x ULN (these latter switched to RA101495). 80 The second study NCT03030183 rather investigated the same regimen as add-on treatment in PNH patients with inadequate response to eculizumab, defined by LDH >1.5x ULN. 81 The POC, proof-of-concept; SC, subcutaneous; IV, intravenous; QOD, quaque die (once a day); BID, bis in die (twice a day); TID, ter in die (thrice a day).
primary endpoint of both study is LDH change; data from these trials are still pending. Likely, biological and even clinical efficacy in terms of control of intravascular hemolysis were seen, since an extension study for patients enrolled in any of the initial study has been launched (NCT03225287). : In combination with eculizumab and likely in monotherapy. *: The possibility of monotherapy is based on available data and current trials rather than on theoretical assumptions. # : Breakthrough intravascular hemolysis may occur because of suboptimal inhibition due to both PK reasons (agents with small therapeutic window or short half-life) or to PD reasons (transiently increased complement activation which may overcome the inhibitory effect of some agents, or activation through pathways which are not inhibited by selective agents)-the risk of breakthrough hemolysis is based on available clinical data and on the specific PK and PD of individual agents. 8: The infectious risk (as compared to eculizumab treatment) is based on the specific target (upstream inhibitors may carry an increased infectious risk), the deepness of inhibition (a deeper and more sustained inhibition may result in an increased infectious risk) and on the possibility to easily rescue complement activity by treatment stopping; IV: intravenous; SC: subcutaneous. @ : Frequency during maintenance treatment; BID: bis in die (twice a day); TID: ter in die (thrice a day).
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opsonization of PNH erythrocytes in vitro. 52 A single ascending dose, phase I study was started in 2011 (NCT01335165); a total of 10 untreated PNH patients were enrolled to investigate tolerability, PK, PD, and immunogenicity of two different formulations of TT30 given as single IV infusion or SC injection. 83 TT30 was safe and well tolerated, with no dose-related safety concern; no immunogenicity was observed. 84 Initial PK and PD data demonstrate that TT30 may achieve pharmacological levels able to inhibit the CAP; this inhibition resulted in transient LDH decrease, eventually proving the concept of therapeutic efficacy of CAP inhibitors in PNH. 84 However, the short half-life of the compound precludes further clinical development of TT30 in its current form, and this program was stopped. 84 
| AMY-101 (Amyndas)
Compstatin is a 13-residue disulfide-bridged peptide 45 which binds to human C3 and C3b, preventing C3 cleavage and C3b incorporation in C3/C5 convertase, eventually abrogating complement activation along all activating pathways. 46 AMY-101/Cp40 is a last generation compstatin analog with increased inhibitory potency and better PK profile, 47 which has been proven effective in vitro to inhibit lysis and C3 fragment opsonization of PNH erythrocytes 48 ; thus, this is an excellent candidate which anticipates to prevent both intravascular and C3-mediated extravascular hemolysis of PNH. 48 After preclinical investigations in nonhuman primates, 85 a phase I single and multiple ascending dose study investigating safety, PK and PD of AMY-101 in healthy volunteers has been completed (NCT03316521). 86 Even if data have not been presented yet, Amyndas has announced a translation program for PNH which includes two separate phase II trials investigating the efficacy of a therapeutic regimen in untreated and poor responder PNH patients. as assessed by LDH. 95 In parallel, Achillion has also announced a phase II trial for PNH patients with inadequate response to eculizumab (EudraCT Number 2016-003526-16); this approach is somehow supported by in vitro data showing a possible synergism between ACH-4471 and eculizumab. 94 As for other upstream complement inhibitors, the prediction is that ACH-4471 in the clinic should prevent both intravascular and extravascular hemolysis of PNH patients; whether the best approach is a monotherapy or a combination treatment will require further clinical investigations.
| LNP023 (Novartis)
Potent and selective orally bioavailable anti-FD and anti-FB agents have been developed by Novartis; all these compound in vitro prevent hemolysis and C3 opsonization of PNH erythrocytes. 56, 59 A phase II trial with the anti-FB agent LNP023 for PNH has been announced (EudraCT Number 2017-000888-33), aiming to investigate safety, PK, PD and efficacy of this inhibitor as add-on therapy in PNH patients with residual hemolysis during eculizumab treatment. 96 The study population includes PNH patients who have LDH >1.5x ULN on stable doses of eculizumab. 96 LNP023 will be given orally 200 mg bi-daily, based on results (not publically available) from a previous phase I study in healthy volunteers. This investigational treatment will be added on top of standard of care, defined as stable doses of eculizumab. Notably, the primary endpoint of this study is the improvement of hemolysis, which will be assessed based on changes in LDH plasma level (C3 deposition will be studied as well). 96 Thus, both inclusion criteria and primary endpoint address the issue of residual intravascular hemolysis during anti-C5 treatment, and may sound a little bit bizarre for an agent which has been designed to target C3-mediated extravascular hemolysis. Nevertheless, one may anticipate that, in case of therapeutic efficacy, the upstream inhibition of CAP will also prevent residual intravascular hemolysis, especially in combination with eculizumab.
However, secondary endpoints may allow to explore the effect of LNP023 on possible C3-mediated extravascular hemolysis, hopefully to better understand the full potential of anti-FB agents as treatment for PNH, possibly even in mono-therapy.
| R E COM M EN D AT ION S F OR F U TU RE I N V ES TI G AT I ONS
What is the best way to improve the current anticomplement treat- anti-C5 therapies aim to achieve a better control of intravascular hemolysis through a deeper inhibition of the terminal complement effector pathway; this might be achieved also combining two distinct anti-C5 agents, as shown in vitro. 23 Indeed, in some trials LDH normalization emerges as primary endpoint, even if the clinical meaning of this goal remains to be proven. After more than 10 years of experience with eculizumab it is obvious that residual complement activity exists due to either PD (eg, excess complement activation leading to massive C5 convertase generation, possibly favored by membrane-bound C3b) 21 and/or PK reasons. 19 Nevertheless, this quasi-complete C5 inhibition was sufficient to generate a great clinical benefit with minimal detrimental effect [2] [3] [4] [5] [6] [7] ; future data will have to prove that a deeper C5 inhibition may result in a better hematological response and in a meaningful clinical benefit without carrying increased safety risk (eg, infectious complications). 65 Based on current understanding of PNH biology during anti-C5 treatment, complete functional knock-down of C5
should limit PD and PK breakthrough, with further reduction of intravascular hemolysis 65 ; however, no more than 15%-20% of patients show laboratory signs of intravascular hemolysis during eculizumab treatment and may benefit from these novel approaches. 19, 97 Conversely, C3-extravascular hemolysis seems the most important mechanism limiting hematological efficacy of eculizumab. 12, 14, [22] [23] [24] [25] [26] This pathogenic mechanism cannot be affected by any of the novel anti-C5 103 and FD. 104 However, it has to be remarked that these severe infectious events mostly occur in the childhood, before that adaptative immunity has established, and most subjects carrying these deficiencies remain alive once the diagnosis is done and proper prophylaxis has been started. This observation, together with the lesson that therapeutic inhibition is not a phenocopy of inherited defi- been also hypothesized that a sub-total inhibition of two key components (eg, C3 or FB/FD in addition to C5) may result in similar clinical results, while preserving a minimal complement activity which could somehow mitigate infectious risks. 20 Future clinical investigations will have to specifically address also this possibility.
| C ONC LUSI ON S
In summary, more than ten novel complement inhibitors are currently in development for PNH; different strategies have been exploited, and their specific pros and cons can be anticipated (Table 3) 
